|
Volumn 22, Issue 2 B, 2002, Pages 1083-1089
|
Comparison of changes in the NSE levels with clinical assessment in the therapy monitoring of patients with SCLC
a a a a a |
Author keywords
Neuron specific enolase (NSE); Small cell lung cancer (SCLC); Therapy monitoring
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CARBOPLATIN;
CISPLATIN;
DOXORUBICIN;
ETOPOSIDE;
NEURON SPECIFIC ENOLASE;
TUMOR MARKER;
ADULT;
AGED;
ARTICLE;
CANCER COMBINATION CHEMOTHERAPY;
CANCER GROWTH;
CANCER RECURRENCE;
CANCER REGRESSION;
CANCER SURVIVAL;
COMPARATIVE STUDY;
FEMALE;
HUMAN;
LUNG SMALL CELL CANCER;
MAJOR CLINICAL STUDY;
MALE;
PATIENT MONITORING;
PRIORITY JOURNAL;
PROGNOSIS;
TREATMENT OUTCOME;
ADULT;
AGED;
AGED, 80 AND OVER;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CARBOPLATIN;
CARCINOMA, SMALL CELL;
CISPLATIN;
COMBINED MODALITY THERAPY;
DOXORUBICIN;
ETOPOSIDE;
FEMALE;
HUMANS;
LUNG NEOPLASMS;
MALE;
MIDDLE AGED;
MONITORING, PHYSIOLOGIC;
PHOSPHOPYRUVATE HYDRATASE;
PREDICTIVE VALUE OF TESTS;
SURVIVAL RATE;
|
EID: 0036329329
PISSN: 02507005
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
Times cited : (21)
|
References (27)
|